An estimate of the risk of movement disorders associated with the chronic use of clebopride.
Sempere
A P
AP
Department of Neurology, Segovia General Hospital, Spain.
Duarte
J
J
García
F
F
Cabezas
C
C
Coria
F
F
Clavería
L E
LE
D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D004415:Dyspepsia / Q000188:drug therapy; D006801:Humans; D011446:Prospective Studies
D001549:Benzamides; D018492:Dopamine Antagonists; C014417:clebopride